News

The secure online e-prescribing portal is available to healthcare providers in the US, interested in a clinically validated, peer reviewed, non-pharmacologic alternative to narcotic and NSAID pain medications

Furiex Pharmaceuticals, under its agreement with Takeda, is eligible to receive royalties and sales-based milestones if trelagliptin succinate is approved and marketed in Japan. Takeda Pharmaceutical has submitted

Polycythemia vera a chronic, incurable blood cancer associated with an overproduction of blood cells. Novartis announced that the Phase III study of Jakavi has met its primary endpoint

The FDA approval will allow the company to start its US based Phase III study in adult patients with ADHD, and patient enrollment is expected to start shortly.

TrialCTA is a cloud-based Software-as-a-Service (SaaS) application that helps Clinical Research Organizations (CRO’s), medical device and pharmaceutical companies manage and track the complex, global clinical trial contracts related

At the new GMP manufacturing facility, the company has implemented its proprietary, fully automated 3D cell expansion manufacturing platform that uses its patented high-throughput culturing technologies, 3D bioreactors,

Hypogonadism (commonly known as Low-T) is related with a deficiency or absence of the male hormone testosterone. The medicine is indicated to produce serum testosterone levels in the

The patent, entitled ‘Single-Walled Carbon Nanotube/Sirna Complexes And Methods Related Thereto’, will extend the intellectual property coverage of Ensysce and add to the extensive package of patents for

Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50% higher plasma concentrations than did the previously